What is the appropriate management for a 1.6 cm branch‑duct intraductal papillary mucinous neoplasm that increased from 0.8 cm three months ago, with a borderline‑high carbohydrate antigen 19‑9 level of 37 U/mL and MRI showing internal linear arterially enhancing solid components?

Surgical Resection is Indicated

This patient requires immediate surgical evaluation and resection because the lesion demonstrates multiple high-risk features that collectively mandate operative intervention: extremely rapid growth (doubling in 3 months), presence of internal solid components on MRI, and borderline-elevated CA 19-9. 1, 2

Critical Risk Factors Present

Rapid Growth Rate

• The cyst doubled from 0.8 cm to 1.6 cm in just 3 months, representing a growth rate of approximately 32 mm/year 2
• This exceeds the European guideline threshold of ≥5 mm/year for a relative surgical indication by more than sixfold 1, 2
• Growth rate ≥5 mm/year is associated with a 20-fold higher risk of malignant progression and approximately 45% 5-year malignancy risk in branch-duct IPMN <30 mm 2
• This aggressive growth pattern indicates high-risk biology requiring surgical intervention 2

Internal Solid Components

• MRI demonstrates "internal linear arterially enhancing solid components" which represents either:
  • Enhancing mural nodules (absolute indication if ≥5 mm; relative indication if <5 mm) 1, 2
  • Solid tissue within the cyst that significantly increases malignancy risk approximately 8-fold 1
• The presence of any enhancing solid component, particularly when combined with other risk factors, strongly suggests malignant transformation 1, 3

Borderline CA 19-9 Elevation

• CA 19-9 at 37 U/mL meets the exact threshold (>37 U/mL) for a relative surgical indication per European guidelines 1, 2
• At this cutoff, CA 19-9 demonstrates 74% positive predictive value and 81.7% diagnostic accuracy for invasive IPMN 1, 4
• 74% of patients with invasive IPMN have elevated CA 19-9, compared to only 14% with non-invasive tumors 4
• This marker must be interpreted in the absence of jaundice or biliary obstruction, which can falsely elevate values 1, 2

Multiple Relative Indications = Surgical Referral

European guidelines explicitly state that the coexistence of multiple relative indications markedly raises malignancy risk and warrants surgical evaluation 1, 2. This patient has at least three:

1. Growth rate ≥5 mm/year (actually 32 mm/year) 1, 2
2. CA 19-9 ≥37 U/mL 1, 2
3. Enhancing solid components 1, 2

Pre-Operative Evaluation Required

Endoscopic Ultrasound with Fine-Needle Aspiration

• EUS-FNA should be performed before surgery to:
  • Precisely characterize the solid components and determine if mural nodules are ≥5 mm (which would constitute an absolute indication) 1, 2
  • Obtain cytology, as high-grade dysplasia or malignancy on cytology is an absolute indication for surgery 1, 2
  • EUS has 73-85% sensitivity and 71-100% specificity for detecting mural nodules ≥5 mm, outperforming CT/MRI 2, 5
  • EUS detects mural nodules missed by CT/MRI in approximately 28% of malignant cases 5

Assess for Additional Absolute Indications

Confirm absence of:

• Main pancreatic duct (MPD) diameter ≥10 mm (absolute indication) 1, 2
• Clinical jaundice (absolute indication) 1, 2
• MPD diameter 5-9.9 mm is a relative indication and is associated with malignancy 1, 3, 5

Surgical Approach

Oncologic resection with standard lymphadenectomy is the preferred procedure 1, 2, because:

• The presence of absolute or multiple relative indications mandates complete oncologic resection 1, 2
• Intraoperative frozen-section analysis of pancreatic resection margins should be performed to ensure negative margins 2
• Five-year disease-free survival after complete resection of IPMN with high-risk features is approximately 96%, though operative morbidity remains significant 2

Assessment of Surgical Fitness

Comprehensive multidisciplinary evaluation of surgical candidacy, comorbidities, and life expectancy is essential before proceeding 1, 2, because:

• Patients with significant comorbidities may not tolerate major pancreatic resection 1
• Even a single relative indication may justify surgery in patients with substantial comorbidities when balanced against life expectancy 1, 2

If Patient Declines or is Unfit for Surgery

For non-surgical candidates, intensified surveillance with imaging every 3 months during the first year is advised 2, with:

• Immediate surgical re-evaluation if further cyst growth, new symptoms, or rising CA 19-9 occurs 2
• Recognition that conservative management carries substantial risk given the documented aggressive growth pattern 2

Post-Operative Surveillance

Lifelong surveillance of the pancreatic remnant is mandatory after partial pancreatectomy 1, 2, because:

• Recurrence of IPMN or development of pancreatic ductal adenocarcinoma can occur in the remnant pancreas 1, 2
• Benign IPMN recurrence has been observed up to 8 years after resection 5

Critical Pitfall to Avoid

Do not be falsely reassured by the small absolute cyst size (1.6 cm) 1, 2. The European guidelines emphasize that even small IPMNs may harbor high-grade dysplasia or cancer, and predictive value improves when multiple risk factors are considered together rather than size alone 1, 2. The combination of rapid growth, solid components, and elevated CA 19-9 supersedes size considerations.